Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Abstract A116: HRAS^G12S mutant mediates resistance to a PI3Kα inhibitor CYH33 in esophageal squamous cell carcinomas

Yuxiang Wang, Xu Zhang, Qingyang Ma, Xi Zhang, Chunhao Yang, Cun Tan, Landing Hu, Jian Ding, Linghua Meng

Mol Cancer Ther (2019) 18 (12_Supplement): A116.

https://doi.org/10.1158/1535-7163.TARG-19-A116

Published: 01 December 2019

View article titled, Abstract A116: HRASG12S mutant mediates resistance to a PI3Kα inhibitor CYH33 in esophageal squamous cell carcinomas

Journal Articles

The Secretome Engages STAT3 to Favor a Cytokine-rich Microenvironment in Mediating Acquired Resistance to FGFR Inhibitors

Xinyi Wang, Jing Ai, Hongyan Liu, Xia Peng, Hui Chen, Yi Chen, Yi Su, Aijun Shen, Xun Huang, Jian Ding, Meiyu Geng

Mol Cancer Ther (2019) 18 (3): 667–679.

https://doi.org/10.1158/1535-7163.MCT-18-0179

Published: 01 March 2019

View article titled, The Secretome Engages STAT3 to Favor a Cytokine-rich Microenvironment in Mediating Acquired Resistance to FGFR Inhibitors

Includes: Supplementary data

Journal Articles

Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models

Jing Ai, Yi Chen, Xia Peng, Yinchun Ji, Yong Xi, Yanyan Shen, Xinying Yang, Yi Su, Yiming Sun, Yinglei Gao, Yuchi Ma, Bing Xiong, Jingkang Shen, Jian Ding, Meiyu Geng

Mol Cancer Ther (2018) 17 (4): 751–762.

https://doi.org/10.1158/1535-7163.MCT-17-0368

Published: 01 April 2018

View article titled, Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models

Includes: Supplementary data

Journal Articles

Abstract B008: PD-1/PDL-1 blockade remarkably regulates abundance of gut commensal microbiota in a murine syngeneic tumor model

WenQing Yang, Jian Ding, Xiangchao Gu, Fei Chen, Juan Zhang, Qian Shi

Mol Cancer Ther (2018) 17 (1_Supplement): B008.

https://doi.org/10.1158/1535-7163.TARG-17-B008

Published: 01 January 2018

View article titled, Abstract B008: PD-1/PDL-1 blockade remarkably regulates abundance of gut commensal microbiota in a murine syngeneic tumor model

Journal Articles

Abstract B078: MiXenoTM: a fast and efficient humanized tumor model system for in vivo efficacy evaluation of novel immunotherapeutics

Lan Zhang, Juan Zhang, Meng Qiao, Xuefei Yan, Jian Ding, Fei Chen, Xiaoyu An, Weibin Tan, Xiaoyan Fu, WenQing Yang, Qian Shi

Mol Cancer Ther (2018) 17 (1_Supplement): B078.

https://doi.org/10.1158/1535-7163.TARG-17-B078

Published: 01 January 2018

View article titled, Abstract B078: MiXenoTM: a fast and efficient humanized tumor model system for in vivo efficacy evaluation of novel immunotherapeutics

Journal Articles

MCL-1 Degradation Mediated by JNK Activation via MEKK1/TAK1-MKK4 Contributes to Anticancer Activity of New Tubulin Inhibitor MT189

Wei Wang, Ying-Qing Wang, Tao Meng, Jun-Mei Yi, Xia-Juan Huan, Lan-Ping Ma, Lin-Jiang Tong, Yi Chen, Jian Ding, Jing-Kang Shen, Ze-Hong Miao

Mol Cancer Ther (2014) 13 (6): 1480–1491.

https://doi.org/10.1158/1535-7163.MCT-13-0629

Published: 04 June 2014

View article titled, MCL-1 Degradation Mediated by JNK Activation via MEKK1/TAK1-MKK4 Contributes to Anticancer Activity of New Tubulin Inhibitor MT189

Includes: Supplementary data

Journal Articles

Abstract B99: Discovery of 2,4-diarylaminopyrimidine SOMCL-12-81 as a potent inhibitor targeting both wild and mutant ALK kinases.

Zilan Song, Jing Ai, Zhiqing Liu, Xia Peng, Yi Chen, Jian Ding, Meiyu Geng, Ao Zhang

Mol Cancer Ther (2013) 12 (11_Supplement): B99.

https://doi.org/10.1158/1535-7163.TARG-13-B99

Published: 01 November 2013

View article titled, Abstract B99: Discovery of 2,4-diarylaminopyrimidine SOMCL-12-81 as a potent inhibitor targeting both wild and mutant ALK kinases.

Journal Articles

Abstract B285: A novel, potent, highly selective inhibitor of c-Met kinase, Simm559, inhibits c-Met-dependent neoplastic phenotypes in vitro and in vivo.

Jing Ai, ZhengSheng Zhan, Ying Wang, Fang Chen, Xia Peng, Yi Chen, Yinchun Ji, Jian Ding, Meiyu Geng, Wenhu Duan

Mol Cancer Ther (2013) 12 (11_Supplement): B285.

https://doi.org/10.1158/1535-7163.TARG-13-B285

Published: 01 November 2013

View article titled, Abstract B285: A novel, potent, highly selective inhibitor of c-Met kinase, Simm559, inhibits c-Met-dependent neoplastic phenotypes in vitro and in vivo.

Journal Articles

Discovery of the Novel mTOR Inhibitor and Its Antitumor Activities In Vitro and In Vivo

Hua Xie, Mee-Hyun Lee, Feng Zhu, Kanamata Reddy, Zunnan Huang, Dong Joon Kim, Yan Li, Cong Peng, Do Young Lim, Soouk Kang, Sung Keun Jung, Xiang Li, Haitao Li, Weiya Ma, Ronald A. Lubet, Jian Ding, Ann M. Bode, Zigang Dong

Mol Cancer Ther (2013) 12 (6): 950–958.

https://doi.org/10.1158/1535-7163.MCT-12-1241

Published: 09 June 2013

View article titled, Discovery of the Novel mTOR Inhibitor and Its Antitumor Activities In Vitro and In Vivo

Journal Articles

Abstract C50: AST‐6, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, inhibits tumor growth both in vitro and in vivo

Hua Xie, Lipin Lin, Linjiang Tong, Yong Jiang, Yi Wang, Xiaowei Zhang, Meiyu Geng, Jianhui Guo, Jian Ding

Mol Cancer Ther (2009) 8 (12_Supplement): C50.

https://doi.org/10.1158/1535-7163.TARG-09-C50

Published: 10 December 2009

View article titled, Abstract C50: AST‐6, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, inhibits tumor growth both in vitro and in vivo

Journal Articles

Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecins

Min Huang, Ze-Hong Miao, Hong Zhu, Yu-Jun Cai, Wei Lu, Jian Ding

Mol Cancer Ther (2008) 7 (6): 1440–1449.

https://doi.org/10.1158/1535-7163.MCT-07-2116

Published: 19 June 2008

View article titled, Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecins

Includes: Supplementary data

Journal Articles

MFTZ-1, an actinomycetes subspecies–derived antitumor macrolide, functions as a novel topoisomerase II poison

Cheng-Ying Xie, Hong Zhu, Li-Ping Lin, Ze-Hong Miao, Mei-Yu Geng, Yu-Jun Cai, Yi Chen, Hua-Jun Zhao, Hai-Bin Luo, Xiong-Wen Zhang, Li-Ming Fan, Yue-Mao Shen, Jian Ding

Mol Cancer Ther (2007) 6 (11): 3059–3070.

https://doi.org/10.1158/1535-7163.MCT-07-0014

Published: 19 November 2007

View article titled, MFTZ-1, an actinomycetes subspecies–derived antitumor macrolide, functions as a novel topoisomerase II poison

Journal Articles

Gambogic acid inhibits the catalytic activity of human topoisomerase IIα by binding to its ATPase domain

Yuxin Qin, Linghua Meng, Chaoxin Hu, Wenhu Duan, Zhili Zuo, Liping Lin, Xiongwen Zhang, Jian Ding

Mol Cancer Ther (2007) 6 (9): 2429–2440.

https://doi.org/10.1158/1535-7163.MCT-07-0147

Published: 17 September 2007

View article titled, Gambogic acid inhibits the catalytic activity of human topoisomerase IIα by binding to its ATPase domain

Journal Articles

R16, a novel amonafide analogue, induces apoptosis and G₂-M arrest via poisoning topoisomerase II

Hong Zhu, Min Huang, Fan Yang, Yi Chen, Ze-Hong Miao, Xu-Hong Qian, Yu-Fang Xu, Yu-Xin Qin, Hai-Bin Luo, Xu Shen, Mei-Yu Geng, Yu-Jun Cai, Jian Ding

Mol Cancer Ther (2007) 6 (2): 484–495.

https://doi.org/10.1158/1535-7163.MCT-06-0584

Published: 16 February 2007

View article titled, R16, a novel amonafide analogue, induces apoptosis and G2-M arrest via poisoning topoisomerase II

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract A116: HRAS^G12S mutant mediates resistance to a PI3Kα inhibitor CYH33 in esophageal squamous cell carcinomas

The Secretome Engages STAT3 to Favor a Cytokine-rich Microenvironment in Mediating Acquired Resistance to FGFR Inhibitors

Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models

Abstract B008: PD-1/PDL-1 blockade remarkably regulates abundance of gut commensal microbiota in a murine syngeneic tumor model

Abstract B078: MiXenoTM: a fast and efficient humanized tumor model system for in vivo efficacy evaluation of novel immunotherapeutics

MCL-1 Degradation Mediated by JNK Activation via MEKK1/TAK1-MKK4 Contributes to Anticancer Activity of New Tubulin Inhibitor MT189

Abstract B99: Discovery of 2,4-diarylaminopyrimidine SOMCL-12-81 as a potent inhibitor targeting both wild and mutant ALK kinases.

Abstract B285: A novel, potent, highly selective inhibitor of c-Met kinase, Simm559, inhibits c-Met-dependent neoplastic phenotypes in vitro and in vivo.

Discovery of the Novel mTOR Inhibitor and Its Antitumor Activities In Vitro and In Vivo

Abstract C50: AST‐6, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, inhibits tumor growth both in vitro and in vivo

Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecins

MFTZ-1, an actinomycetes subspecies–derived antitumor macrolide, functions as a novel topoisomerase II poison

Gambogic acid inhibits the catalytic activity of human topoisomerase IIα by binding to its ATPase domain

R16, a novel amonafide analogue, induces apoptosis and G₂-M arrest via poisoning topoisomerase II

Email alerts

AACR Journals

Resources

AACR Journals
on Social Media

Update search

Email alerts

AACR Journals

Resources

AACR Journals on Social Media

This Feature Is Available To Subscribers Only

AACR Journals
on Social Media